This is a working overview of certificate of analysis, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-06-03 and is reviewed periodically as new material appears.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water; stock solutions use organic solvent. |
| Storage | -20°C, desiccated, protected from light | Limits hydrolysis and photodegradation. |
| Analytical method | HPLC-UV/MS | Used for identity and purity assessment. |
| Synonyms | SR9009, Stenabolic | Naming varies by supplier. |
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
=== Pharmacodynamics === Noribogainalog acts as a potent serotonin 5-HT2A receptor partial agonist (EC50Tooltip half-maximal effective concentration ≈ 90 nM; EmaxTooltip maximal efficacy = 35–45%). It is also a partial agonist of the serotonin 5-HT6 receptor (Emax = 29%), whereas it is not an agonist of the serotonin 5-HT2B and 5-HT7 receptors. The drug additionally has activity as a dopamine transporter (DAT) chaperone. Noribogainalog does not affect locomotor activity, does not produce the head-twitch response, and does not affect various other physiological and behavioral measures. However, it does produce analgesic effects that can be diminished by the serotonin 5-HT2A receptor antagonist ketanserin. In addition, a subsequent study found that the highest assessed dose produced significant hypolocomotion and that the drug also reduced fentanyl self-administration.
=== Scotland to England in 2007 === On 29 April 2007, he began walking again at John o' Groats and arrived at Land's End on 8 June, having covered 900 miles (1,400 km) in 6 weeks. On the walk in Britain he visited 20 hospices and raised £10,000 for hospice through sales of his Beyond the Setting Sun book.
=== Working with governors === As treasurer, Kennedy often clashed with governors and state legislators from both political parties, especially over spending and tax increases. He advocated for reducing state bureaucracy by cutting unnecessary state government jobs. In 2006, Kennedy criticized Governor Kathleen Blanco for including more than $9 million in spending he deemed "pork". He sent Blanco a six-page document of suggested cuts she could make as line-item vetoes. Kennedy said his list was "based upon the fact that many of the entities do not appear to be government entities, the lack of information about many of the items or entities, and that many of the items should have been considered through the entire process and/or included in other appropriate places in the budget to ensure proper public scrutiny, input and accountability." During his third term as treasurer, Kennedy devised a 24-point plan by which the state could save money. Governor Bobby Jindal said Kennedy could "streamline" his own department. Many of Kennedy's ideas were derived from the Louisiana Commission for Streamlining Government, on which he served in his official capacity as treasurer. Kennedy later accused Jindal's administration of check kiting, a controversial accounting practice whereby the governor took money from the 2014-2015 budget to cover debts from the 2013-2014 budget.
Sources: en.wikipedia.org
== History == In 2006, Rich Reiff and George Fox purchased several publications from Reed Business Information's New Product Division, formerly known as Gordon Publications, with the backing of private equity provided by Catalyst Investors. Also in 2006, the company launched the FindGuru business-to-business-focused search engine as a revised and rebranded ReedLink tool originally available from Reed Business Information. In 2011, ABM acquired Continuity Insights and Vicon Publishing. Vicon Publishing was renamed by ABM to Vicon Business Media as a subsidiary operated out of New Hampshire. In 2013 ABM acquired eMedia Vitals. In 2014, the firm was sold by Catalyst to Owners Resource Group (ORG), a private equity firm based in Austin, Texas, for undisclosed terms. This acquisition was ORG's first foray in the media business. In March 2014, co-founder Richard Reiff left the firm, leaving the CEO position vacant, though there is an indication that Jim Lonergan was brought in as CEO by the new owner. In 2018, Lonergan was replaced by Bruce Cummings and the company rebranded, changing its name to Advantage Business Marketing. On June 11, 2019, Cummings told all employees that the company was filing for bankruptcy and immediately closing. Staff had until the end of the day to vacate the premises. No severance package was given to employees, customers lost much of what they'd purchased, and many vendors were never paid.
It has been cultivated in sunny, temperate climates and traded for over 3,500 years across Eurasia, spreading through Asia via cultural exchange and conquest. Its recorded history is attested as early as a 7th-century BC Assyrian botanical treatise. Saffron is an essential ingredient in Persian cuisine used in dishes such as chelow and tahdig, stews like khoresh-e fesenjan, and desserts including sholeh-zard and bastani sonnati. Additional historical uses include traditional medicine, dyeing, perfumery, and religious rituals.
=== Celebrity protests of business expansion === In 2006, Paul McCartney protested a proposed $175 million animal testing laboratory by the company in Chandler, Arizona. However, the laboratory opened in 2009.
Sources: en.wikipedia.org
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.
The solid is generally kept cold, dry, and protected from light. Solutions are often frozen in single-use aliquots to reduce repeated freeze-thaw cycles.
It indicates a material sold for laboratory study, not for human use. The label does not guarantee pharmaceutical purity, sterility, or regulatory approval.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.